AMEX:NNVC News | QuoteStream

acceswire

NanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the Trial

SHELTON, CT / ACCESS Newswire / July 28, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that it is eagerly awaiting regulatory approval to begin a Phase II Clinical Trial of NV-387 Oral Gummie…

ACCESS Newswire en_IN 28/7/2026, 08:30 pm GMT+8

EconomyStocksUS

NNVC

tradingview

NanoViricides Launches At-The-Market Stock Offering With D. Boral Capital; 2% Commission

NanoViricides entered into an At Market Issuance Sales Agreement with D. Boral Capital to sell common stock from time to time under its shelf registration. Shares may be sold on NYSE American or other markets, or through privately negotiated transactions with the company’s consent. The Sales Agent…

TradingView en_IN 18/7/2026, 04:53 am GMT+8

StocksUS

NNVC

acceswire

Research Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" Interview of the Company's President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily

SHELTON, CT / ACCESS Newswire / July 8, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, reports that a Coverage Initiating Research Report on the Company by an Independent Analyst has been published, dat…

ACCESS Newswire en_IN 8/7/2026, 08:30 pm GMT+8

StocksUS